There were two sets of experiments. In the first set, rats were subjected to collagenase-induced ICH. ICH rats were then randomly assigned to receive the lactate dehydrogenase (LDH) inhibitor oxamate (OXA, Sigma-Aldrich, artificial cerebrospinal fluid [aCSF], ALZET® Osmotic Pumps [0.5 µL/h], i.c.v.) at concentrations of 10, 25, or 50 mM. OXA was infused immediately after the collagenase injection. In the Sham group, rats only received 0.9% sterile saline and aCSF in the corresponding sites. Rats were killed on days 7 and 14 post-ICH. In the second set, intact rats received an infusion of sodium l -lactate (l-lactate, Sigma-Aldrich, 0.9% sterile saline, ALZET® Osmotic Pumps [0.5 µL/h]) into the right globus pallidus at concentrations of 5, 10, or 25 mM. Some rats in the l -lactate group received BAY11-7082 (BAY, Sigma-Aldrich, aCSF, 5 µL, i.c.v.) to inhibit NF-κB at concentrations of 25, 50, or 100 µM. BAY was injected immediately after the l -lactate-infusion with a cannula implantation system (RWD Life Science). BAY was injected once per day. In the Sham group, rats only received 0.9% sterile saline and aCSF in the corresponding sites. Rats were killed on days 2 and 7 after the l -lactate infusion.
Alzet osmotic pumps
Manufactured by Merck Group
ALZET® Osmotic Pumps are miniature, implantable drug delivery devices designed to provide controlled and continuous release of substances into laboratory animals. The pumps operate based on the principle of osmosis, using the body's own fluids to power the delivery of the substance contained within the pump.
Automatically generated - may contain errors
Lab products found in correlation
L name, by Merck Group (1 mentions)
Foxn1nu foxn1nu, by Jackson ImmunoResearch (1 mentions)
Sodium chloride (nacl), by Merck Group (1 mentions)
Alzet model 1004, by Durect (1 mentions)
Phr1084, by Merck Group (1 mentions)
Cannula implantation system, by RWD Life Science (1 mentions)
L lactate, by Merck Group (1 mentions)
Bay11 7082, by Merck Group (1 mentions)
Ang 2, by Merck Group (1 mentions)
C57bl 6 mice, by Charles River Laboratories (1 mentions)
4 protocols using alzet osmotic pumps
1
Oxamate Inhibits LDH in ICH Rats
2
Chronic Murine Cardiomyopathy Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Male wild‐type (WT; strain C57BL/6J; Harlan Laboratories, Indianapolis, IN), Nude (strain J:NU, Foxn1nu/Foxn1nu; The Jackson Laboratory, Bar Harbor, ME), and severe combined immunodeficient (SCID; strain B6.CB17‐Prkdcscid/SzJ C57BL/6 background; The Jackson Laboratory) mice were used in a CMP model modified from Oestreicher et al.15 CMP groups were given drinking water containing 0.1 mg/mL of l ‐NAME (Sigma‐Aldrich, St. Louis, MO) and 1% NaCl (Sigma‐Aldrich). After 1 week of acclimatization to water, mice were anesthetized with inhaled isoflurane and implanted with subcutaneous osmotic minipumps (ALZET model 1004; DURECT Corporation ALZET Osmotic Pumps, Cupertino, CA) that delivered angiotensin‐II (Ang‐II; Sigma‐Aldrich) at a rate of 0.7 mg/kg per day for an additional 4 weeks. All mice were sacrificed at the end of the fifth week. All experiments used 3‐month‐old mice, which demonstrated decreased function, but a higher survival rate, compared to older mice (5–8 months old). All experiments were performed under approval of the Houston Methodist Hospital Research Institute Institutional Animal Care and Use Committee (Houston, TX).
3
Cardiac Hypertrophy in Aging Mice
4
Ang II-Induced Cardiac Remodeling in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Male C57BL/6 mice were purchased from the Vital River Laboratory Animal Technology Company of Beijing in China. All animal experiments were approved by the Institutional Animal Care and Use Committee of Capital Medical University. Hypertensive cardiac remodelling was induced in 8‐ to 12‐week‐old male mice by chronic subcutaneous infusion of Ang II (A9525, Sigma‐Aldrich) at a dose of 1,500 ng/kg/min using the ALZET® Osmotic Pumps (Model 1007D) for 7 days or 1,000 ng/kg/min using the pumps (Model 1002D) for 14 days. The control mice were infused with saline for 7 or 14 days. For shikonin treatment, mice were randomized to be intraperitoneally injected with either vehicle or shikonin at a dose of 1.25 mg/kg 3 times per week. All mice were analysed by echocardiography and haemodynamic measurements at 7 days or 14 days.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!